Fly News Breaks for March 11, 2015
ACT
Mar 11, 2015 | 07:12 EDT
JPMorgan reinstated Actavis with an Overweight rating saying post the Allergan acquisition, the drug maker is a "highly diversified, global pharmaceutical company with critical mass in several attractive therapeutic categories." The firm raised its price target for shares to $375 from $310.
News For ACT From the Last 2 Days
There are no results for your query ACT